The committee noted the treatment regimens were more aggressive in this trial compared with the other trials included in the review. The committee agreed that while there is some evidence that rapid blood pressure lowering treatment is beneficial, there may be an increase in adverse renal events, and they were concerned about the lack of evidence in people who are frail. Taking this into account, the committee agreed that rapid blood pressure lowering treatment should be considered as a treatment option except for the groups highlighted in recommendation 1.5.7. There was evidence that a moderate reduction of up to 60 mmHg within the first hour was associated with better outcomes such as functional independence. A reduction of more than 60 mmHg within 1 hour was associated with significantly worse outcomes such as renal failure, early neurological deterioration, and death, compared with standard treatment. Therefore, the committee agreed that a large reduction of 60 mmHg or more within 1 hour should be avoided. The 2019 guideline included a 130 mmHg lower target limit. However, the committee were concerned that a narrow range would be too restrictive, and the variation in the class of drugs used in practice means it is difficult to predict the blood pressure reduction. The committee decided to remove the 130 mmHg lower target limit. The committee considered the potential risk of systolic blood pressure dropping too low but noted that this potential concern is addressed by the avoidance of a large reduction of 60 mmHg or more within 1 hour. The committee also agreed that the target systolic blood pressure and the systolic blood pressure reduction should be made into a separate recommendation (1.5.6). There was little evidence on people presenting beyond 6 hours or those with a systolic blood pressure over 220 mmHg. 